Choksi Laboratories Limited has officially submitted its unaudited financial results for the third quarter of FY26 ended December 31, 2025, to BSE Limited under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The analytical testing and calibration laboratory group demonstrated strong operational performance with significant improvements across key financial metrics, alongside strategic board changes approved during the meeting held on February 7, 2026.

Financial Performance Overview

The company's Q3FY26 results showed remarkable improvement compared to the corresponding period in the previous year, with net profit witnessing exceptional growth:

For the nine-month period ended December 31, 2025, the company reported revenue from operations of ₹3,318.37 lakhs compared to ₹3,038.28 lakhs in the corresponding nine-month period of FY25, representing a growth of 9.22%. The nine-month net profit increased substantially to ₹93.75 lakhs from ₹60.20 lakhs in the previous year.

Exceptional Item and Income Components

During Q3FY26, Choksi Laboratories recorded an exceptional gain of ₹77.80 lakhs from the sale of an office flat. This non-recurring transaction was classified as an exceptional item as it does not form part of the company's ordinary operating activities. Other income for the quarter totaled ₹13.34 lakhs, comprising interest income of ₹0.58 lakhs, interest on IT refund of ₹13.26 lakhs, cash back on credit card of ₹0.21 lakhs, and forex gain of ₹1.10 lakhs.

Board Leadership Changes

The board meeting resulted in significant leadership transitions that will shape the company's governance structure:

Mr. Ritik Pavecha brings qualified expertise in audit, assurance, corporate compliance, governance, and regulatory advisory. The company affirmed that he is not debarred from holding directorship by SEBI or any other authority and holds no equity shares in the company.

Regulatory Compliance and Audit

The financial results were duly reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on February 7, 2026. The results were prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013. Prateek Jain & Co., Chartered Accountants (FRN-009494C), provided the independent auditor's review report, confirming that the results comply with applicable recognition and measurement principles and disclosure requirements under listing regulations.

Operational Metrics

Choksi Laboratories continues to operate under a single business segment of "Analysis and Testing" as per Ind AS 108 Operating Segments. The company's total expenses for Q3FY26 were ₹1,083.23 lakhs compared to ₹1,021.02 lakhs in Q3FY25. Key expense components included employee benefits expense of ₹454.10 lakhs, other expenses of ₹183.39 lakhs, and power & fuel charges of ₹130.44 lakhs. The meeting commenced at 12:30 PM and concluded at 2:35 PM at the company's registered office in Indore, Madhya Pradesh.

Source:

Choksi Laboratories Limited has announced the resignation of Mrs. Meenaxi Patidar from her position as Non-Executive Independent Director, effective January 09, 2026. The resignation was communicated to the Bombay Stock Exchange on January 10, 2026, in compliance with regulatory requirements.

Resignation Details

Mrs. Patidar, who holds Director Identification Number (DIN) 10206356, submitted her resignation via email on January 09, 2026. She cited preoccupation and personal commitments as the primary reasons for stepping down from her directorial role.

Impact on Board Committees

Following her resignation as Independent Director, Mrs. Patidar has also ceased her involvement in key board committees. She was serving as a Member of the Audit Committee and held the position of Chairperson of the Nomination & Remuneration Committee.

The departure creates vacancies in these critical governance committees that will need to be addressed by the company's board of directors in due course.

Regulatory Compliance

Choksi Laboratories Limited has fulfilled all mandatory disclosure requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive details as required by the SEBI Master Circular dated November 11, 2024.

Director's Confirmation

In her resignation letter addressed to the Board of Directors, Mrs. Patidar expressed gratitude for the trust and support received during her tenure. She specifically confirmed that there are no other material reasons for her resignation beyond the preoccupation and personal commitments mentioned in her letter.

The resignation was processed by Company Secretary and Compliance Officer Prakhar Dubey, who signed the regulatory filing on January 10, 2026. Mrs. Patidar wished the company continued success and prosperity in her farewell message to the board and company members.